Radiopharmaceutical · developed by Molecular Partners
Pb-MP0712 is a lead-212 radiopharmaceutical that is designed to target DLL3-expressing cells. It is being studied in neuroendocrine carcinomas, including large cell neuroendocrine carcinoma, extrapulmonary neuroendocrine carcinoma and small cell lung cancer.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07278479 | Phase 1/2 | Large Cell Neuroendocrine Carcinoma | Recruiting | MOLN |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)Gastroenteropancreatic NEC (GEP NEC)Large Cell Neuroendocrine CarcinomaNEC of the BladderOther DLL3 Expressing epNECSmall Cell Lung Cancer (SCLC)
See MOLN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
MOLN catalysts and pipeline →